statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment...

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans...

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data...

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Hold" from Brokerages

StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Free Report) from a sell rating to a hold rating in a research report released on Friday morning. Separately, JPMorgan Chase...

Enanta Pharmaceuticals (NASDAQ:ENTA) Raised to "Hold" at StockNews.com

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on...

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.com

This price move could be a signal that ENTA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Enanta Pharmaceuticals (ENTA, $16.54) price may drop as it broke higher Bollinger Band on Mar 27, 2024

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA  Get Free Report) have received an average recommendation of Hold from the six analysts that are covering the firm...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of "Hold" from Brokerages

This is a Bearish indicator signaling ENTA's price could decline from here. Traders may explore shorting the stock or put options...

Enanta Pharmaceuticals (ENTA, $14.54) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 12, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R...

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Volume	1,938.00
52-Wk High	$37.14
52-Wk Low	$8.08

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.34	--	--	N/A
Q1'24	-$1.23	-$1.58	-28.87%	MISSED
Q4'23	-$2.12	-$1.33	37.39%	BEAT
Q3'23	-$2.25	-$1.86	17.28%	BEAT
Q2'23	-$1.96	-$1.79	8.83%	BEAT

ENTA Enanta Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals